ZURA 241220 2.50P (ZURA241220P2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

ZURA241220P2500

Watchlist

0.20
-0.10-33.33%

15min DelayClose Dec 20 16:00 ET

0.28High0.20Low

Intraday

5D
Daily

News

Leerink Partners Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $12
Moomoo NewsDec 20 13:31 ET · Ratings
Zura Bio (ZURA) Receives a Buy From Piper Sandler
TipRanksDec 12 06:46 ET · Ratings
Leerink Partners Maintains Zura Bio(ZURA.US) With Buy Rating, Cuts Target Price to $12
Moomoo NewsDec 12 02:33 ET · Ratings
Optimistic Outlook on Zura Bio: Tibulizumab's Potential and Market Opportunity
TipRanksDec 12 02:06 ET
Express News | Cantor Fitzgerald Reiterates Overweight on Zura Bioto Overweight
BenzingaDec 11 11:21 ET
Express News | Zura Bio Ltd : Leerink Partners Cuts Target Price to $12 From $15
ReutersDec 11 08:23 ET

Comments

Jaguar8

Nov 14 15:32

NEWS

$Zura Bio (ZURA.US)$
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Methodman10

Oct 17 14:32

$Zura Bio (ZURA.US)$ big move ahead. daily chart looks great

Trytosaveabit

Jun 14 05:04

Update

$Zura Bio (ZURA.US)$ Zura Bio Ltd: Tibulizumab (Zb-106) Was Well Tolerated and Neutralized Il-17a and Baff in a Phase 1 Study in Patients With Sjogren's Syndrome! Presents data at EULAR 2024

Drosen21

Jun 12 08:09

Hedgies may be confused over at Cantor…

$Zura Bio (ZURA.US)$ One is overweight and another to buy 🤫

Jaguar8

Jun 3 06:31

NEWS

$Zura Bio (ZURA.US)$
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...